SV-BR-1-GM + Cyclophosphamide + Interferon infiltration of the inoculation site + Retifanlimab + Treatment of Physician's Choice
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Trial Timeline
Dec 5, 2023 → Jun 1, 2028
NCT ID
NCT06072612About SV-BR-1-GM + Cyclophosphamide + Interferon infiltration of the inoculation site + Retifanlimab + Treatment of Physician's Choice
SV-BR-1-GM + Cyclophosphamide + Interferon infiltration of the inoculation site + Retifanlimab + Treatment of Physician's Choice is a phase 3 stage product being developed by BriaCell Therapeutics for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06072612. Target conditions include Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06072612 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Cancer